Generic Medicine Info
Indications and Dosage
Adult: As 2nd line drug: 15-20 mg/kg daily as a single dose. Max: 1 g daily.
Child: As 2nd line drug: 10-20 mg/kg daily as a single dose. Max dose: 750 mg daily.
Hypersensitivity. Severe hepatic disease, porphyria.
Special Precautions
Difficulty in managing DM. Monitor blood glucose, thyroid and visual function. Perform LFT before and during treatment with protionamide. Caution in patients with psychiatric illness or depression. Pregnancy and lactation.
Adverse Reactions
Anorexia, excessive salivation, metallic taste, nausea, vomiting, abdominal pain, diarrhoea. Peripheral and/or optic neuritis, psychiatric disturbances e.g. depression, anxiety, psychosis, postural hypotension. Jaundice, hepatitis. Thrombocytopenia, skin rashes, stomatitis, gynaecomastia.
Drug Interactions
Increased neurotoxic effects with cycloserine.
Potentially Fatal: Increased incidence of hepatotoxicity with rifampicin.
Description: Protionamide inhibits peptide synthesis. It is active against mycobacteria species. Bacteriostatic against M. tuberculosis. Also active against atypical mycobacteria e.g. M. kansasii and some strains of M. avium complex, and M. leprae.
Onset: 30-60 min.
Duration: 12-16 hr.
Absorption: Readily absorbed form the GI tract (oral); peak plasma concentrations after 2 hr.
Distribution: Widely distributed into body fluids and CSF.
Metabolism: Converted to sulfoxide (active) and other metabolites.
Excretion: Via urine (<1% as unchanged).
MIMS Class
Anti-TB Agents
Disclaimer: This information is independently developed by MIMS based on Protionamide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in